Data is not available at this time.
Visiodent SA operates in the dental health sector, specializing in cloud-based management software for dental practices and health centers through its Veasy platform. The company serves a global market, leveraging its 1983 founding and subsidiary status under Groupe Visiodent SAS to establish credibility in healthcare IT. Its core revenue model revolves around subscription-based SaaS solutions, enabling dental professionals to streamline administrative and clinical workflows. Visiodent competes in the niche but growing healthcare information services segment, where digitization and efficiency are increasingly prioritized. The company’s market position is bolstered by its long-standing industry presence and focus on dental-specific software, differentiating it from broader healthcare IT providers. While the sector is competitive, Visiodent’s specialized offering and European base provide a stable foothold in a market transitioning toward cloud-based solutions.
In FY 2020, Visiodent reported revenue of €9.09 million, with net income of €644,555, reflecting a net margin of approximately 7.1%. The company generated €1.99 million in operating cash flow, indicating solid cash conversion from operations. Capital expenditures of €1.20 million suggest ongoing investments in its software platform, aligning with its SaaS-focused model.
The company’s diluted EPS of €0.14 demonstrates modest but positive earnings power. With operating cash flow covering capital expenditures, Visiodent maintains adequate capital efficiency. Its SaaS model likely supports recurring revenue, though further details on customer retention or growth metrics would clarify long-term earnings sustainability.
Visiodent’s balance sheet shows €3.07 million in cash and equivalents against €2.61 million in total debt, indicating a manageable leverage position. The net cash position provides liquidity for operations and potential growth initiatives, though the debt level warrants monitoring given the company’s modest scale.
The company paid a dividend of €1.83 per share in FY 2020, a notable distribution relative to its EPS. This suggests a shareholder-friendly policy, though sustainability depends on future profitability. Growth trends are unclear without historical data, but the healthcare IT sector’s expansion could benefit Visiodent’s niche focus.
With no reported market capitalization and a beta of -0.35, Visiodent appears to be a micro-cap stock with low correlation to broader markets. The lack of valuation multiples limits insight, but the dividend yield and SaaS model may attract income and growth investors, respectively.
Visiodent’s strategic advantages include its specialized dental software and established industry presence. The shift toward digital healthcare solutions could drive demand for its offerings, though competition and execution risks remain. The outlook hinges on its ability to scale its SaaS platform while maintaining profitability and cash flow.
Company filings, Euronext Paris
show cash flow forecast
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | 2035 | 2036 | 2037 | 2038 | 2039 | 2040 | 2041 | 2042 | 2043 | 2044 | 2045 | |
INCOME STATEMENT | ||||||||||||||||||||||||||
| Revenue growth rate, % | NaN | |||||||||||||||||||||||||
| Revenue, $ | NaN | |||||||||||||||||||||||||
| Variable operating expenses, $m | NaN | |||||||||||||||||||||||||
| Fixed operating expenses, $m | NaN | |||||||||||||||||||||||||
| Total operating expenses, $m | NaN | |||||||||||||||||||||||||
| Operating income, $m | NaN | |||||||||||||||||||||||||
| EBITDA, $m | NaN | |||||||||||||||||||||||||
| Interest expense (income), $m | NaN | |||||||||||||||||||||||||
| Earnings before tax, $m | NaN | |||||||||||||||||||||||||
| Tax expense, $m | NaN | |||||||||||||||||||||||||
| Net income, $m | NaN | |||||||||||||||||||||||||
BALANCE SHEET | ||||||||||||||||||||||||||
| Cash and short-term investments, $m | NaN | |||||||||||||||||||||||||
| Total assets, $m | NaN | |||||||||||||||||||||||||
| Adjusted assets (=assets-cash), $m | NaN | |||||||||||||||||||||||||
| Average production assets, $m | NaN | |||||||||||||||||||||||||
| Working capital, $m | NaN | |||||||||||||||||||||||||
| Total debt, $m | NaN | |||||||||||||||||||||||||
| Total liabilities, $m | NaN | |||||||||||||||||||||||||
| Total equity, $m | NaN | |||||||||||||||||||||||||
| Debt-to-equity ratio | NaN | |||||||||||||||||||||||||
| Adjusted equity ratio | NaN | |||||||||||||||||||||||||
CASH FLOW | ||||||||||||||||||||||||||
| Net income, $m | NaN | |||||||||||||||||||||||||
| Depreciation, amort., depletion, $m | NaN | |||||||||||||||||||||||||
| Funds from operations, $m | NaN | |||||||||||||||||||||||||
| Change in working capital, $m | NaN | |||||||||||||||||||||||||
| Cash from operations, $m | NaN | |||||||||||||||||||||||||
| Maintenance CAPEX, $m | NaN | |||||||||||||||||||||||||
| New CAPEX, $m | NaN | |||||||||||||||||||||||||
| Total CAPEX, $m | NaN | |||||||||||||||||||||||||
| Free cash flow, $m | NaN | |||||||||||||||||||||||||
| Issuance/(repurchase) of shares, $m | NaN | |||||||||||||||||||||||||
| Retained Cash Flow, $m | NaN | |||||||||||||||||||||||||
| Pot'l extraordinary dividend, $m | NaN | |||||||||||||||||||||||||
| Cash available for distribution, $m | NaN | |||||||||||||||||||||||||
| Discount rate, % | NaN | |||||||||||||||||||||||||
| PV of cash for distribution, $m | NaN | |||||||||||||||||||||||||
| Current shareholders' claim on cash, % | NaN |